Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
18 p, 451.1 KB EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies / Kiesewetter, B. (Department of Medicine i. Clinical Division of Oncology. Medical University of Vienna) ; Cherny, N.I. (Cancer Pain and Palliative Medicine Service. Department of Medical Oncology. Shaare Zedek Medical Center) ; Boissel, N. (Adolescent and Young Adult Hematology Unit. Diderot University Paris Faculty of Medicine) ; Cerisoli, F. (European Hematology Association) ; Dafni, U. (Frontier Science Foundation-Hellas) ; De Vries, E.G.E. (Department of Medical Oncology. University Medical Center Groningen) ; Ghia, P. (Universita Vita e Salute San Raffaele) ; Gökbuget, N. (Department of Hematology/Oncology. Goethe University) ; González-Calle, V. (Department of Hematology and Instituto de Investigación Biomédica de Salamanca-IBSAL. University Hospital of Salamanca) ; Huntly, B. (Cambridge Stem Cell Institute. Department of Haematology. University of Cambridge) ; Jäger, U. (Department of Medicine i. Clinical Division of Hematology and Hemostaseology. Medical University of Vienna) ; Latino, N.J. (Head Office. European Society for Medical Oncology) ; Douillard, J.Y. (Head Office. European Society for Medical Oncology) ; Malcovati, L. (Department of Hematology Oncology. Fondazione IRCCS Policlinico San Matteo) ; Mateos, M.V. (Department of Hematology and Instituto de Investigación Biomédica de Salamanca-IBSAL. University Hospital of Salamanca) ; Ossenkoppele, G.J. (Department of Hematology. VU University Medical Centre Amsterdam) ; Porkka, K. (Department of Hematology. Helsinki University Hospital Comprehensive Cancer Center) ; Raderer, M. (Department of Medicine i. Clinical Division of Oncology. Medical University of Vienna) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Scarfò, L. (Universita Vita e Salute San Raffaele) ; Wester, R. (Department of Hematology. Erasmus MC Cancer Institute) ; Zygoura, P. (Frontier Science Foundation-Hellas) ; Sonneveld, P. (Department of Radiation Oncology. Erasmus MC Cancer Institute) ; Universitat Autònoma de Barcelona
Objective Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). [...]
2020 - 10.1136/esmoopen-2019-000611
ESMO Open, Vol. 5 Núm. 1 (20 2020) , p. e000611  
2.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, P (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
3.
11 p, 693.2 KB ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation / Malcikova, J. (Brno, Czech Republic) ; Tausch, E. (Ulm, Germany) ; Rossi, D. (Bellinzona, Switzerland) ; Sutton, L. A. (Stockholm, Sweden) ; Soussi, T. (Stockholm, Sweden) ; Zenz, T. (Zürich, Switzerland) ; Kater, A. P. (Amsterdam, The Netherlands) ; Niemann, C. U. (Copenhagen, Denmark) ; González De Castro, David (Belfast, UK) ; Davi, F. (Paris, France) ; Gonzalez Diaz, M. (Salamanca, Spain) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gaidano, G. (Novara, Italy) ; Stamatopoulos, K. (Thessaloniki, Greece) ; Rosenquist, R. (Stockholm, Sweden) ; Stilgenbauer, S. (Ulm, Germany) ; Ghia, P. (Milan, Italy) ; Pospisilova, S. (Brno, Czech Republic) ; Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080  

See also: similar author names
4 Ghia, P.
1 Ghia, Pooja
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.